Retinalamin

Last Updated: August 2026

Retinalamin® is a peptide bioregulator for the eye — a complex of water-soluble polypeptide fractions (molecular weight ≤10 kDa) isolated from cattle retina. It is a retinoprotector used clinically in Russia (and some CIS countries) for retinal and optic-nerve disorders. Importantly, it is a polypeptide mixture, not a single defined peptide, and it is not approved by the FDA or EMA. It is supplied for research use only outside its approved markets.

What is Retinalamin and how does it work?

Retinalamin is a tissue-specific polypeptide extract — in the same broad family as other tissue-derived bioregulators — that acts directly on the retina to activate cell metabolism, support Müller-cell function and glutamate handling, improve the interaction between pigment epithelium and photoreceptors, normalize vascular permeability, and protect retinal neurons from oxidative stress and excitotoxicity. Because it is a complex mixture rather than one molecule, its activity is attributed to the fraction as a whole. Note that it is sometimes conflated with the tetrapeptide Epithalon (AEDG), which has separate retinoprotective research — but Retinalamin is a polypeptide complex, not the AEDG sequence.

What does the research on Retinalamin show?

Retinalamin has been used and studied in Russian ophthalmology since the 1980s, with clinical reports in diabetic retinopathy, retinal dystrophy/abiotrophy, glaucomatous optic neuropathy, and related conditions, plus cell-culture work showing tissue-specific stimulation of retinal and pigment-epithelial cells. The bulk of the clinical literature is Russian and predates modern multi-center trial standards. Evidence level: Russian clinical use + preclinical; not evaluated by the FDA/EMA.

What are the safety concerns and regulatory status?

Retinalamin is a registered medicine in Russia — State Register of Medicines no. ЛС-000684, a lyophilisate of cattle retinal polypeptides for intramuscular and parabulbar injection (marketed by Geropharm) — approved there for retinal and optic-nerve disorders including compensated primary open-angle glaucoma, diabetic retinopathy, and central and peripheral retinal dystrophies. It is not approved by the FDA or EMA.1 source, and material sold through research-chemical channels is not an approved product outside those markets and its identity cannot be assumed. See the legal status guide.

Why does vendor verification matter, and how does Peptigrity verify?

As a biologically-sourced polypeptide complex, Retinalamin can't be verified by a single expected mass the way a defined peptide can — so purity, composition, and the absence of contaminants (via HPLC and appropriate analytical methods) are the relevant checks, and provenance matters especially for an animal-derived product. Peptigrity collects independent third-party Certificates of Analysis for Retinalamin from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate; the trust score weights lab purity and reviews equally (50/50). See how to read lab results.

Educational information only; not medical advice. Retinalamin is not FDA/EMA-approved. Consult a qualified healthcare provider. Peptigrity does not sell, endorse, or recommend products or vendors.